Lv1
70 积分 2025-10-16 加入
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
2个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
3个月前
已完结
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings
6个月前
已关闭
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
6个月前
已完结
Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era
9个月前
已完结
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
9个月前
已完结
皖公网安备34019202002308
